Novo Nordisk sues Hims & Hers for patent infringement over compounded semaglutide

Novo Nordisk filed a patent infringement suit against Hims & Hers, alleging that its compounded semaglutide products infringe US Patent 8,129,343. Novo asks the court for damages and a permanent ban on the infringing products. Hims responded that it would fight the case, and its shares fell sharply on the news.

• The suit targets Hims' compounded semaglutide products sold for the US market.
• Novo seeks damages and a court order permanently barring the sale of the covered products.
• Novo cited its own testing, which found impurities of up to 86% in compounded injectable semaglutide and up to 75% in compounded oral semaglutide.
• The suit follows Hims' short-lived compounded Wegovy-style pill.